ALGN Stock Recent News

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Align Technology (ALGN) and Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?

The average of price targets set by Wall Street analysts indicates a potential upside of 31.4% in Align Technology (ALGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Align Technology reports first-quarter 2025 financial results, reflecting strength in the Imaging Systems & CAD/CAM Services business segment.

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financial conferences. The presentations, as noted below, will be webcast live via the Investor Relations section of Align T.

Align Technology, Inc. (ALGN) Q1 2025 Earnings Call Transcript

The headline numbers for Align Technology (ALGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Align Technology (ALGN) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $2.14 per share a year ago.

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the first quarter ("Q1'25"). Q1'25 total revenues were $979.3 million, down 1.6% sequentially and down 1.8% year-over-year. Q1'25 total revenues were unfavorably im.

Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.